proposed pathways for who pq listing · require the review of new data by any part of the science...
TRANSCRIPT
![Page 1: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/1.jpg)
ProposedPathwaysforWHOPQListing
![Page 2: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/2.jpg)
BuildingRegulatoryPathways
• KEYPRINCIPLES• Identifythecustomers• Identifyactionsandtheirresponsible parties• Developactionsfroma“customer benefit”mindset• StrivefortheMinimumViable Pathway(MVP)• Eachaction isabuildingblock
•ADEQUACY• EFFICIENCY• FLEXIBILITY
![Page 3: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/3.jpg)
Pre-submissionMeetingTypes
NewProduct
Variation
NewParadigm
ExistingParadigm
![Page 4: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/4.jpg)
Pre-submissionMeetingType
WHOGroupsInvolved
Outcome
New Product,NewParadigm
PQNTDGMP
• Determination ofRegulatoryPathway,existing oradhoc
• VCAGreview ofproposedparadigm• Addressquestions regardingdossier requirementsspecific totheproposedsubmission
NewProduct,Existing Paradigm
PQNTD*GMP*
• Determination ofRegulatoryPathway• New AI,Existing AI,Generic
• Addressquestions regardingdossier requirementsspecific totheproposedsubmission
Variation PQNTD*GMP*
• Determination of Variationtrack(Minor/Major)• Addressquestions regardingdossier requirementsspecific totheproposedsubmission
*Included forNormativeGuidance Consultation
![Page 5: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/5.jpg)
Existing Paradigm
NewAI
LLIN Non-LLIN
ExistingAI
LLIN Non-LLIN
Generic
LLIN Non-LLIN
Non-chemical/Other
NewParadigm
VCAG
Variation
Major Minor Notification
![Page 6: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/6.jpg)
BuildingaRegulatoryPathway– WHOpieces
WHOAction Item Duration(months)
WHOGroups Notes/Outcome
Pre-submissionMeeting 1 PQ,NTD,GMP
Applicanthasclearunderstanding ofpathtosubmission anddossierrequirements
EFFICACY PROTOCOL REVIEW
Phase1EfficacyConsultation 3 PQ,NTD,GMP
Documentedreview ofprotocol,sharedwithapplicant
Phase2EfficacyConsultation 3 PQ,NTD,GMP
Documentedreview ofprotocol,sharedwithapplicant.IncludesreviewofRAtoensurehumansafetyforPhase2trials
Phase3EfficacyConsultation 3 PQ,NTD,GMP
Documentedreview ofprotocol,sharedwithapplicant
![Page 7: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/7.jpg)
BuildingaRegulatoryPathway– WHOpiecesWHOAction Item Duration
(months)WHOGroups Notes/Outcome
Variations
Major 7 PQ Includes labeland/orformulationchangeswhichrequirethereviewofnewdatabyanypartofthescienceorinspections team
Minor 2 PQ Includes labeland/orformulationchangeswhichdonotrequirereviewofnewstudies ordata.
Risk AssessmentDevelopment
CAGP RiskAssessment (RA) 15 CAGP,PQ EvaluationofAIanddevelopment ofRAforPQusePQDecision
PQInterimDecision 1 PQ Onlyassociatedwithnon-generic LLINproducts. Allows WHOtopre-qualifyanLLINforuseduringthePhase3EfficacyTrials.
PQ FinalDecision 4 PQ After reviewingPhase3Efficacydata,PQwillfinalizedecisiontolistproductaspre-qualified.
![Page 8: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/8.jpg)
BuildingaRegulatoryPathway– WHOpiecesWHOAction Item Duration
(months)WHOGroups Notes/Outcome
PRODUCT REVIEWS
New Product,NewParadigm
?? PQ,NTD,GMP
Durationisdependent onthenewparadigm.Completed reviewofanewVCparadigm.
New ProductExistingParadigmNew AIReview 12 PQ Includesscreen, PQandASVCPevaluationofdossiertofinalize
PQreviewoftheNewAI,New Product
ExistingAIReview 12 PQ Includesscreen, PQandASVCPevaluationofdossiertofinalizePQreviewoftheExistingAI,New Product
GenericReview 7 PQ Includesscreen, PQandASVCPevaluationofdossier(includingproductandAIequivalencydetermination)tofinalizePQreviewoftheGeneric,New Product,andlistingdecision
![Page 9: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/9.jpg)
BuildaRegulatoryPathway– ApplicantPieces
ApplicantAction Item Est.Duration(months)
Outcome
DOSSIERDEVELOPMENT
ApplicantDossierDevelopment 24 Finalizedtox,chem,andeco studiesreadytosubmittoWHO,includesanapplicant preparedRAandmayincludeSRARA
Phase1EfficacyTrials 9 FinalizedstudyreportreadytosubmittoWHOforinclusion inRA
Phase2 EfficacyTrials 9 FinalizedstudyreportreadytosubmittoWHOforPhase3Consult
Phase3Efficacy Trials(LLIN) 12 FinalizedstudyreportreadytosubmittoWHOforFinalPQdecision
Phase3Efficacy Trials(non-LLIN) 36 FinalizedstudyreportreadytosubmittoWHOforFinalPQdecision
![Page 10: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/10.jpg)
BuildaRegulatoryPathway– NRAPieces
ApplicantAction Item Duration(months)
Notes/Outcome
Establish NRAs inPQCollaborativeRegistration Procedure (CRP)
6 PQandapplicant willengage NRAsduring thePQProduct reviewprocess inorder toencourageparticipation intheCRP
NRAs’ Approval Decision 3 AfteraPQ interim/final decision, NRAsinvolved inCRP registerproducts within theircountry
![Page 11: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/11.jpg)
EFFICA
CY
Trials
Phase3
Consult NRAAP
PROV
AL
DossierDevelopment
NewAIReview
ExistingAIReview
Phase1Consult
“Let’s Build!!!”
![Page 12: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/12.jpg)
PossiblePathways
Existing Paradigm
NewAI
LLIN Non-LLIN
ExistingAI
LLIN Non-LLIN
Generic
LLIN Non-LLIN
Variation
Minor Major
![Page 13: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/13.jpg)
ExistingParadigm,NewAI,non-LLIN
![Page 14: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/14.jpg)
ExistingParadigm,NewAI,LLIN
![Page 15: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/15.jpg)
ExistingParadigm,ExistingAI,non-LLIN
![Page 16: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/16.jpg)
ExistingParadigm,ExistingAI,LLIN
![Page 17: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/17.jpg)
ExistingParadigm,Generic
![Page 18: Proposed Pathways for WHO PQ Listing · require the review of new data by any part of the science or inspections team Minor 2 PQ Includes label and/or formulation changes which do](https://reader035.vdocument.in/reader035/viewer/2022070919/5fb8db301d5f1505c35909d4/html5/thumbnails/18.jpg)
Variations– MajorandMinor